Suppr超能文献

[铒]氯化铒和[铒]铒-PSMA-617的首次临床前单光子发射计算机断层显像/计算机断层扫描(SPECT/CT)成像及生物分布

First preclinical SPECT/CT imaging and biodistribution of [Er]ErCl and [Er]Er-PSMA-617.

作者信息

Saeedi Saghez Behrad, Rodríguez-Rodríguez Cristina, Esquinas Pedro Luis, Merkens Helen, Bénard François, Radchenko Valery, Yang Hua

机构信息

Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada.

Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC, V6T 1Z1, Canada.

出版信息

EJNMMI Radiopharm Chem. 2024 Dec 18;9(1):90. doi: 10.1186/s41181-024-00312-9.

Abstract

BACKGROUND

Er (t = 10.4 h, E = 47.1 keV (59.4%) and 54.3 keV (14.3%)) is a promising radionuclide suitable for targeted Auger electron therapy of cancer. Er can be produced at a relatively low cost, high yield, and high purity using small medical cyclotrons. As a late lanthanide, Er is easy to label and can be used as a surrogate for other lanthanides or Ac in proof-of-concept studies. In this report, we explore the radiochemistry, in vitro, and in vivo behavior of [Er]ErCl and [Er]Er-PSMA-617 to showcase the application of this radionuclide. Particularly, we report the first phantom and preclinical SPECT imaging of this radionuclide leveraging its characteristic X-ray photon emissions.

RESULTS

The Ho(p,n)Er nuclear reaction using a 13 MeV cyclotron demonstrated production yields of up to 25 ± 5 MBq. µA h at the end of the bombardment. After the purification (4.0 ± 0.5 h) using a sequential combination of cation exchange and extraction chromatography, 4-h irradiation produced up to 1.5 GBq of [Er]ErCl. High molar activity [Er]Er-PSMA-617 was prepared (~ 200 MBq/nmol). [Er]Er-PSMA-617 showed a LogD value of -2.34 ± 0.24 meaning high hydrophilicity of the complex as expected. The stability of [Er]Er-PSMA-617 in saline, human, and mouse serum was studied and showed intact tracer after 12 h in all three cases. [Er]ErCl and [Er]Er-PSMA-617 were both taken up by LNCaP cells. PSMA-617 has IC at nanomolar range for [Er]Er-PSMA-617 in LNCaP cells. SPECT images with preclinical phantoms showed good uniformity, spatial resolution, and quantitative accuracy. SPECT/CT imaging in LNCaP tumor-bearing mice injected with [Er]Er-PSMA-617 showed high tumor uptake and quantitative accuracy when comparing the results to ex vivo biodistribution %IA/g values. Mice injected with [Er]ErCl showed uptake in bone structures and excretion through both liver and kidneys.

CONCLUSIONS

This study demonstrated the preclinical use of Er for the first time. Using [Er]ErCl and [Er]Er-PSMA-617 as examples, the radiochemistry, cell, and animal studies showed that Er can be used as a tool for evaluating targeted radiopharmaceuticals. The X-ray emission from Er can be used for quantitative SPECT imaging in mice.

摘要

背景

铒(半衰期t = 10.4小时,能量E = 47.1 keV(59.4%)和54.3 keV(14.3%))是一种很有前景的放射性核素,适用于癌症的靶向俄歇电子治疗。使用小型医用回旋加速器可以以相对较低的成本、高产率和高纯度生产铒。作为一种晚期镧系元素,铒易于标记,可在概念验证研究中用作其他镧系元素或锕的替代物。在本报告中,我们探索了[铒]氯化铒和[铒]铒-PSMA-617的放射化学、体外和体内行为,以展示这种放射性核素的应用。特别是,我们利用其特征性X射线光子发射报告了该放射性核素的首次体模和临床前SPECT成像。

结果

使用13 MeV回旋加速器的钬(p,n)铒核反应在轰击结束时的产率高达25±5 MBq/µA·h。经过阳离子交换和萃取色谱的顺序组合纯化(4.0±0.5小时)后,4小时的辐照产生了高达1.5 GBq的[铒]氯化铒。制备了高摩尔活度的[铒]铒-PSMA-617(~200 MBq/nmol)。[铒]铒-PSMA-617的LogD值为-2.34±0.24,这意味着该配合物具有预期的高亲水性。研究了[铒]铒-PSMA-617在盐水、人血清和小鼠血清中的稳定性,结果表明在所有三种情况下12小时后示踪剂均保持完整。[铒]氯化铒和[铒]铒-PSMA-617均被LNCaP细胞摄取。PSMA-617对LNCaP细胞中[铒]铒-PSMA-617的抑制浓度在纳摩尔范围内。临床前体模的SPECT图像显示出良好的均匀性、空间分辨率和定量准确性。在注射了[铒]铒-PSMA-617的荷LNCaP肿瘤小鼠中进行的SPECT/CT成像显示,与离体生物分布%IA/g值相比,肿瘤摄取高且定量准确。注射[铒]氯化铒的小鼠在骨骼结构中有摄取,并通过肝脏和肾脏排泄。

结论

本研究首次证明了铒在临床前的应用。以[铒]氯化铒和[铒]铒-PSMA-617为例,放射化学、细胞和动物研究表明,铒可用作评估靶向放射性药物的工具。铒发出的X射线可用于小鼠的定量SPECT成像。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c187/11655927/80057fe2fa88/41181_2024_312_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验